Dorzagliatin pharmacokinetics are characterized by a two-compartment linear pharmacokinetic model with zero- and first-order sequential absorption.

Body weight, age, aspartate aminotransferase, and sex were found to be significant covariates on clearance and volume; however, the impact on steady-state exposure of dorzagliatin is minimal and not expected to be clinically meaningful.

The estimated population parameter values may assist drug labeling and clinicians in the individualization of dorzagliatin dosage regimens.